Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Colon Crohn s disease

Treatment depends on the site of disease. Management of colonic Crohn s disease is very similar to... [Pg.646]

Kotanagi, H., Sone, S., Fukuoka, T., Narisawa, T., Koyama, K., Yagi-sawa, H., Chiba, M., Masamune, O. Liver abscess as the initial manifestation of colonic Crohn s disease report of a case. Japan. J. Surg. 1991 21 348 -351... [Pg.517]

Limberg B (1989) Diagnosis of acute ulcerative colitis and colonic Crohn s disease by colonic sonography. J Clin Ultrasound 17 25-31... [Pg.83]

Respiratory A 44-year-old woman with ileo-colonic Crohn s disease developed pneumonitis while taking methotrexate the symptoms resolved after withdrawal after 4 weeks pulmonary function tests and high-resolution chest computed tomography were normal [69 ]. [Pg.620]

Rice bran fiber has fructo-oligosaccharides - a pre-biotic that helps friendly bacteria to proliferate in the gastrointestinal environment and improves intestinal and colon health (Tomlin and Read, 1988). Recent studies in humans (Kahlon and Chow, 1997) have revealed that rice bran fiber not only normalizes bowel function, but also helps in conditions such as irritable bowel syndrome (IBS), inflammatory bowel disease (IBD) and Crohn s disease, and lowers the lipid levels. Rice bran fiber has been shown to significantly reduce renal stones (Jahnen et al., 1992). It is a good source of fiber in weight loss programs and therapeutic fiber diets for diabetics and heart patients. Fiber diets prevent cancer of the colon and large bowel, control obesity and improve bowel function. [Pg.352]

Comorbid conditions, such as chronic ulcerative colitis, particularly when it involves the entire large intestine, and to lesser extent Crohn s disease, also increase the risk of colon cancer. Overall, persons diagnosed with either disease constitute about 1% to 2% of all new cases of colorectal cancer each year. [Pg.1344]

Sasaki, Y., Hada, R., Nakajima, H., Fukuda, S., Munakata, A., Improved localizing method of radiopill in measurement of entire gastrointestinal pH profiles colonic luminal pH in normal subjects and patients with Crohn s disease, Am. J. Gastroenterol. 1997, 92, 114-118. [Pg.568]

An increasing number of both clinical and laboratory-derived observations support the importance of luminal components in driving the inflammatory response in ulcerative colitis and Crohn s disease. Although its role is unclear, antibiotic therapy is commonly used in clinical practice for the treatment of moderately to severely active ulcerative colitis. Metronidazole and/or ciprofloxacin are currently employed in active Crohn s disease, particularly in patients with colonic involvement and with perianal disease. Rifaximin, a rifamycin-derived antibiotic, is characterized by a wide range of antibacterial activity and a very low systemic absorption. Some preliminary data show its efficacy in severe active ulcerative colitis, pouchitis and prevention of postoperative recurrence in Crohn s disease. [Pg.96]

Ambrose NS, Allan RN, Keighley MR, Burdon DW, Youngs D, Lennard-Jones JE Antibiotic therapy for treatment in relapse of intestinal Crohn s disease. A prospective randomized study. Dis Colon Rectum 1985 28 81-85. [Pg.102]

Suggested Alternatives for Differential Diagnosis Amebiasis, cholera, salmonellosis, schisto-mosis, yersiniosis, Clostridium difficile colitis, colon cancer, Crohn s disease, ulcerative colitis. [Pg.517]

There are two forms of idiopathic inflammatory bowel disease (IBD) ulcerative colitis, a mucosal inflammatory condition confined to the rectum and colon, and Crohn s disease, a transmural inflammation of GI mucosa that may occur in any part of the GI tract. The etiologies of both conditions are unknown, but they may have a common pathogenetic mechanism. [Pg.295]

Sulfasalazine is more effective when Crohn s disease involves the colon. [Pg.302]

Metronidazole (given orally up to 20 mg/kg/day) may be useful in some patients with Crohn s disease, particularly in patients with colonic or ileocolonic involvement or those with perineal disease. The combination of metronidazole with ciprofloxacin is efficacious in some patients. [Pg.302]

A medicinal example is found with 5-aminosalicylic acid O-sulfate (5-ASA sulfate, 9.90). 5-ASA is an agent for the treatment of ulcerative colitis and Crohn s disease of the large intestine, but it is unstable in the gastric juice. 5-ASA sulfate was, therefore, developed as a prodrug able to reach its site of action (the colon) following oral application [173]. In healthy human... [Pg.595]

Crohn s disease is granulomatous and in most cases it is a simultaneous disease of the ileum and colon. The primarily inflamed region is the distal ileum, and all intestinal layers are thickened. The mucosal surface is reddened, nodular, and cobblestone-Uke, with mnltiple linear ulcerations. The mucosal layer is thickened by inflammatory infiltrate, the submucosa and serosa by fibrosis, and the serosa by hypertrophy. Chronic nlcerative colitis is a systemic disease that starts at the rectum or the sigmoid colon and progresses proximally to involve the entire left side of the colon. The colonic crypts are the first sites of cell damage and death, and the disease primarily involves the mucosal layer of the intestine. [Pg.160]

Inflammatory Bowel Disease (IBD) comprises several diseases, including ulcerative colitis and Crohn s disease. Ulcerative cohtis is a disease of the colon, originating in the rectum and extending proximally to a variable extent. It frequently affects the entire colon but never... [Pg.174]

Crohn s disease Crohn s disease patients are known to have an increased incidence of Gl and certain extraintestinal cancers. There have been some reports in the medical literature of breast and colon cancer in Crohn s disease patients who have been treated with metronidazole at high doses for extended periods of time. Candidiasis Candidiasis may present more prominent symptoms during therapy and requires treatment with a candicidal agent. [Pg.1657]

Sulfasalazine was the first of the 5-aminosalicylic acid (5-ASA) congeners that was shown to be effective in the treatment of active Crohn s disease with involvement of the colon and of ulcerative colitis. [Pg.380]

Sulfasalazine treatment results in an 85% remission rate in mild to moderate ulcerative colitis. Termination of therapy leads to an 80% relapse within the next year. In Crohn s disease, sulfasalazine acts primarily on involved colonic mucosa, although remission of ileal disease also has been reported. The National Cooperative Crohn s Disease Study found sulfasalazine to be better in the treatment of colonic disease, while corticosteroids were judged better in the treatment of small bowel disease. Since sulfasalazine does not prevent relapse of Crohn s disease once remission is achieved, maintenance therapy is not characteristically used. [Pg.480]

A 21-year-old woman comes with her parents to discuss therapeutic options for Crohn s disease. She was diagnosed with Crohn s disease 2 years ago, and it involves her terminal ileum and proximal colon, as confirmed by colonoscopy and small bowel radiography. She was initially treated with mesalamine and budesonide with good response but over the last 2 months she has had a relapse of symptoms. She is experiencing fatigue, cramping abdominal pains, and nonbloody diarrhea up to 10 times daily, and she has had a 15-lb weight loss. [Pg.1309]

ASA drugs induce and maintain remission in ulcerative colitis and are considered to be the first-line agents for treatment of mild to moderate active ulcerative colitis. Their efficacy in Crohn s disease is unproven, although many clinicians use 5-ASA agents as first-line therapy for mild to moderate disease involving the colon or distal ileum. [Pg.1327]

The effectiveness of 5-ASA therapy depends in part on achieving high drug concentration at the site of active disease. Thus, 5-ASA suppositories or enemas are useful in patients with ulcerative colitis or Crohn s disease confined to the rectum (proctitis) or distal colon (proctosigmoiditis). In patients with ulcerative colitis or Crohn s colitis that extends to the proximal colon, both the azo compounds and mesalamine formulations are useful. For the treatment of Crohn s disease involving the small bowel, mesalamine compounds, which release 5-ASA in the small intestine, have a theoretic advantage over the azo compounds. [Pg.1327]

Oral controlled-release budesonide (9 mg/d) is commonly used in the treatment of mild to moderate Crohn s disease involving the ileum and proximal colon. It appears to be slightly less effective than prednisolone in achieving clinical remission, but has significantly less adverse systemic effects. [Pg.1327]

Sulfasalazine. Salicylazosulfapyridine or Azulfadine [599-79-1] (2-hydroxy-5-[[4[(2-pyridylamino)sulfonyl]-phenyl]azo] benzoic acid) (15) is a light brownish yellow-to-bright yellow fine powder that is practically tasteless and odorless. It melts at ca 255°C with decomposition, is very slightly soluble in ethanol, is practically insoluble in water, diethyl ether, chloroform, and benzene, and is soluble in aqueous solutions of alkali hydroxides. Sulfasalazine may be made by the synthesis described in Reference 13. It is not used as an antidiarrheal as such, but is indicated for the treatment of inflammatory bowel diseases such as ulcerative colitis and Crohn s disease. Its action is purported to result from the breakdown in the colon to 5-aminosalicylic acid [89-57-6] (5-AS A) and sulfapyridine [144-83-2]. It may cause infertility in males, as well as producing idiosyncratic reactions in some patients these reactions have been attributed to the sulfa component of the compound. The mechanism of 5-ASA is attributed to inhibition of the arachidonic acid cascade preventing leukotriene B4 production and the ability to scavenge oxygen free radicals. The active component appears to be 5-aminosalicylic acid. [Pg.203]

This time controlled release tablet with a designated lag time followed by a rapid release may provide an alternative to site-specific delivery of drugs with optimal absorption windows or colonic delivery of drugs that are sensitive to low pH or enzyme action for the treatment of localized conditions such as ulcerative colitis, Crohn s disease, and irritable bowel syndrome (IBS). Also, by controlling a predetermined lag time of drug from dosage form, the release behavior can be matched with the body s circadian rhythm pattern in chronotherapy. [Pg.164]

Conjugated bile salts are normally absorbed in the terminal ileum. Disease of the terminal ileum (eg, Crohn s disease) or surgical resection leads to malabsorption of bile salts, which may cause colonic secretory diarrhea. The bile salt binding resins cholestyramine or colestipol may decrease diarrhea caused by excess fecal bile acids (see Chapter 35 Agents Used in Hyperlipidemia). The usual dose is 4-5 g one to three times daily before meals. Side effects include bloating, flatulence, constipation, and fecal impaction. In patients with diminished circulating bile acid pools, further removal of bile acids may lead to an exacerbation of fat malabsorption. These agents bind a number... [Pg.1489]


See other pages where Colon Crohn s disease is mentioned: [Pg.114]    [Pg.360]    [Pg.114]    [Pg.360]    [Pg.242]    [Pg.149]    [Pg.525]    [Pg.195]    [Pg.564]    [Pg.57]    [Pg.97]    [Pg.181]    [Pg.39]    [Pg.56]    [Pg.89]    [Pg.176]    [Pg.480]    [Pg.481]    [Pg.135]    [Pg.1320]    [Pg.1639]    [Pg.28]    [Pg.1348]    [Pg.248]   


SEARCH



Crohn

Crohn disease

Crohn’s disease

© 2024 chempedia.info